Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
World game at war: why some European nations have threatened a World Cup boycott 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
NEW ORLEANS, April 23, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (Nasdaq:MYGN), if they purchased the Company’s securities between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Utah.
What You May Do
If you purchased securities of Myriad and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mygn/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 19, 2018.
About the Lawsuit
Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to the Company’s hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
